Skip to content
ES
MARKETS / NASDAQ / ALKS
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Alkermes PLC. ALKS

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.5B
▼ 5.2% YoY
$241.7M
▼ 34.2% YoY
$480.3M
▲ 18.4% YoY
In brief

What this company does

Alkermes plc has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. ARISTADA is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. VIVITROL is a once-monthly, non-narcotic, injectable medication approved in the U.S. for the treatment of alcohol dependence in patients able to abstain from alcohol in an outpatient setting prior to initiation of treatment, and for the prevention of relapse to opioid dependence following opioid detoxification. It manufactures ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and microspheres for RISPERDAL CONSTA at its Wilmington, Ohio facility. It is headquartered in Ireland and also has a corporate office and R&D center in Massachusetts. As of February 20, 2026, it had approximately 2,050 full time employees, of which approximately 1,950 were based in the U.S. and approximately 100 were based in Ireland.

Written from the business description in Alkermes plc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.5B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.5 · Net income 0.2
0.80B1.60B-0.08B-0.16B200920112013201520172019202120232025
Compound annual growth
+9.9%
+7.3%
+8.9%
+14.8%
+33.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
16 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 17.2% · Net 16.4%
10%20%-10%-20%-30%200920112013201520172019202120232025
ROE
FY2025 · ROE 14.7%
10%20%30%-5%-10%-15%200920112013201520172019202120232025
Gross margin86.7%
Operating margin17.2%
Net margin16.4%
Return on assets10.6%
EBITDAUSD 281.1M

Each USD of equity produced 15 cents of profit this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 480.3
200M400M-40M-80M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2024 · Dividends — · Net buybacks 200.3
80M160M20092024
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 2.5B
EquityUSD 1.8B
CashUSD 388.6M
Current ratio3.55×

Equity funds 73% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.51.61.71.11.21.01.21.10.90.70.60.60.60.60.40.20.2
Operating income $B0.30.40.4−0.00.1−0.1−0.2−0.1−0.1−0.2−0.2−0.10.00.1−0.1−0.0−0.0
EBITDA $B0.30.40.50.10.2−0.0−0.10.0−0.0−0.1−0.10.0·0.2−0.0−0.0−0.0
Income tax $B0.00.1−0.10.00.00.0−0.00.00.0−0.00.00.0−0.00.0−0.0−0.0−0.0
Net income $B0.20.40.4−0.2−0.0−0.1−0.2−0.1−0.2−0.2−0.2−0.00.00.0−0.1−0.0−0.0
Free cash flow $B0.50.40.4−0.00.10.0−0.00.0−0.0−0.1−0.1−0.0·0.1−0.0−0.0−0.0
EPS, diluted $1.432.172.10−0.97−0.29−0.70−1.25−0.90−1.03−1.38−1.52−0.210.140.18−0.99−0.48−0.42
Dividend / sh $·················
Payout %·················
ROE %14.727.531.7−14.7−4.4−10.3−17.4−11.7−13.1−16.5−16.8−2.42.02.8−18.2−11.3−9.6
Shares out B0.170.160.170.160.160.160.160.160.150.150.150.150.140.000.000.10·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 13 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image